Page last updated: 2024-11-08

dacuronium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dacuronium: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID218421
CHEMBL ID3138543
MeSH IDM0044587

Synonyms (14)

Synonym
dacuronium
43021-45-0
[(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-17-hydroxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate
17-hydroxypancuronium
piperidinium, 3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis-(1-methyl-
vd6l56zvx1 ,
unii-vd6l56zvx1
dacuronium ion
3.alpha.,17.beta.-dihydroxy-5.alpha.-androstan-2.beta.,16.beta.-ylene)bis-(1-methylpiperidinium) 3-acetate
dacuronium cation
CHEMBL3138543
Q27291768
1,1'-((2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-3-acetoxy-17-hydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthrene-2,16-diyl)bis(1-methylpiperidin-1-ium)
AKOS040745721

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"To compare two oral contraceptive pills, both containing 150 micrograms desogestrel, but with either 20 micrograms (Mercilon) or 30 micrograms (Marvelon/Desolett) ethinyl oestradiol (EE), regarding reliability, cycle control and side effect profile."( Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund, M; Røde, A; Westergaard, J, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (31.25)18.7374
1990's6 (37.50)18.2507
2000's5 (31.25)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.09 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (47.06%)5.53%
Reviews2 (11.76%)6.00%
Case Studies1 (5.88%)4.05%
Observational0 (0.00%)0.25%
Other6 (35.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Pain Relief and Inflammatory Status in Women With Surgically Confirmed Endometriosis Treated With Atorvastatin, Oral Contraceptive or Combined Oral Contraceptives and Atorvastatin: Open Randomized Controlled Trial [NCT00675779]44 participants (Anticipated)Interventional2008-04-30Active, not recruiting
Open, Randomized, Parallel Multi-center Comparison of Cycle Control and Safety of the Oral Contraceptive Yasmin 20 in a 24-day Regimen vs. Mercilon for 7 Cycles in 440 Healthy Female Volunteers [NCT00624130]Phase 3453 participants (Actual)Interventional2004-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]